You are here

Home » CERID Bibliography

CERID Bibliography

Export 44 results:
Author Title Type [ Year(Asc)]
Filters: Keyword is Plasmodium falciparum  [Clear All Filters]
2012
Wolofsky KT, Ayi K, Branch DR, Hult AK, Olsson ML, W Liles C, Cserti-Gazdewich CM, Kain KC. ABO blood groups influence macrophage-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes. PLoS Pathog. 2012 ;8(10):e1002942.
Marwaha A, White J, El Mazouni F, Creason SA, Kokkonda S, Buckner FS, Charman SA, Phillips MA, Rathod PK. Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase. J Med Chem. 2012 ;55(17):7425-36.
Caballero MC, Pedroni MJ, Palmer GH, Suarez CE, Davitt C, Lau AOT. Characterization of acyl carrier protein and LytB in Babesia bovis apicoplast. Mol Biochem Parasitol. 2012 ;181(2):125-33.
MacMullin G, Mackenzie R, Lau R, Khang J, Zhang H, Rajwans N, W Liles C, Pillai DR. Host immune response in returning travellers infected with malaria. Malar J. 2012 ;11:148.
Murphy SC, Prentice JL, Williamson K, Wallis CK, Fang FC, Fried M, Pinzon C, Wang R, Talley AK, Kappe SHI, et al. Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am J Trop Med Hyg. 2012 ;86(3):383-94.
Ojo KK, Pfander C, Mueller NR, Burstroem C, Larson ET, Bryan CM, Fox AMW, Reid MC, Johnson SM, Murphy RC, et al. Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest. 2012 ;122(6):2301-5.
2011
Crowther GJ, Napuli AJ, Gilligan JH, Gagaring K, Borboa R, Francek C, Chen Z, Dagostino EF, Stockmyer JB, Wang Y, et al. Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol. 2011 ;175(1):21-9.
Higgins SJ, Kain KC, W Liles C. Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria. Expert Rev Anti Infect Ther. 2011 ;9(9):803-19.
Gujjar R, El Mazouni F, White KL, White J, Creason S, Shackleford DM, Deng X, Charman WN, Bathurst I, Burrows J, et al. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem. 2011 ;54(11):3935-49.
2010
Guiguemde AW, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, et al. Chemical genetics of Plasmodium falciparum. Nature. 2010 ;465(7296):311-5.
Odom AR, Van Voorhis WC. Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Mol Biochem Parasitol. 2010 ;170(2):108-11.
Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang S-Y, Bucher CJ, Floyd RJ, Katt WP, et al. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J Med Chem. 2010 ;53(19):6867-88.
2009
Ayi K, W Liles C, Gros P, Kain KC. Adenosine triphosphate depletion of erythrocytes simulates the phenotype associated with pyruvate kinase deficiency and confers protection against Plasmodium falciparum in vitro. J Infect Dis. 2009 ;200(8):1289-99.
Conroy A, Serghides L, Finney C, Owino SO, Kumar S, D Gowda C, W Liles C, Moore JM, Kain KC. C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria. PLoS One. 2009 ;4(3):e4953.
Boggild AK, Page AV, Keystone JS, Morris AM, W Liles C. Delay in diagnosis: malaria in a returning traveller. CMAJ. 2009 ;180(11):1129-31.
Gujjar R, Marwaha A, El Mazouni F, White J, White KL, Creason S, Shackleford DM, Baldwin J, Charman WN, Buckner FS, et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem. 2009 ;52(7):1864-72.
Serghides L, Patel SN, Ayi K, Lu Z, D Gowda C, W Liles C, Kain KC. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J Infect Dis. 2009 ;199(10):1536-45.
Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, Krudsood S, Looareesuwan S, John CC, W Liles C, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One. 2009 ;4(3):e4912.
Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, et al. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol. 2009 ;16(2):181-92.
Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, Wilairatana P, W Liles C, Looareesuwan S, Kain KC. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2009 ;49(6):841-9.
2008
Olepu S, Suryadevara PK, Rivas K, Yokoyama K, Verlinde CLMJ, Chakrabarti D, Van Voorhis WC, Gelb MH. 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett. 2008 ;18(2):494-7.
Bulbule VJ, Rivas K, Verlinde CLMJ, Van Voorhis WC, Gelb MH. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem. 2008 ;51(3):384-7.
Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R. Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci. 2008 ;29(2):62-71.
Lovegrove FE, Peña-Castillo L, W Liles C, Hughes TR, Kain KC. Plasmodium falciparum shows transcriptional versatility within the human host. Trends Parasitol. 2008 ;24(7):288-91.
Larson ET, Deng W, Krumm BE, Napuli A, Mueller N, Van Voorhis WC, Buckner FS, Fan E, Lauricella A, Detitta G, et al. Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol. 2008 ;381(4):975-88.

Pages